2019
DOI: 10.1101/522383
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Scarless Enriched selection of Genome edited Human Pluripotent Stem Cells Using Induced Drug Resistance

Abstract: An efficient gene editing technique for use in human pluripotent stem cells (hPSCs) would have great potential value in regenerative medicine, as well as in drug discovery based on isogenic human disease models. However, the extremely low efficiency of gene editing in hPSCs is a major technical hurdle that remains to be resolved. Previously, we demonstrated that YM155, a survivin inhibitor developed as an anti-cancer drug, induces highly selective cell death in undifferentiated hPSCs. In this study, we demonst… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 44 publications
(68 reference statements)
0
1
0
Order By: Relevance
“…Based on the role of the solute carrier protein SLC35F2 in the import of YM155 (Winter et al, 2014), and differences in the cytotoxicity of YM155 toward different cancer cell types (Winter et al, 2014), we hypothesized that the stemotoxic activity of YM155 and its analogs may be mediated by SLC35F2. To explore this, cell death of hESCs after treatment with various stemotoxic YM155 analogs was compared with control hESCs (wild type: WT) and SLC35F2 knockout (KO) hESCs generated using the CRISPR/CAS9 system (Figures 6A,B and Figure S4; Kim et al, 2019). As predicted, the stemotoxic activity of YM155 and its analogs was completely lost in KO hESCs, while cell death was evident in WT hESCs (Figures 6C,D).…”
Section: Resultsmentioning
confidence: 99%
“…Based on the role of the solute carrier protein SLC35F2 in the import of YM155 (Winter et al, 2014), and differences in the cytotoxicity of YM155 toward different cancer cell types (Winter et al, 2014), we hypothesized that the stemotoxic activity of YM155 and its analogs may be mediated by SLC35F2. To explore this, cell death of hESCs after treatment with various stemotoxic YM155 analogs was compared with control hESCs (wild type: WT) and SLC35F2 knockout (KO) hESCs generated using the CRISPR/CAS9 system (Figures 6A,B and Figure S4; Kim et al, 2019). As predicted, the stemotoxic activity of YM155 and its analogs was completely lost in KO hESCs, while cell death was evident in WT hESCs (Figures 6C,D).…”
Section: Resultsmentioning
confidence: 99%